Amicus Therapeutics is a company you should know about because it is a leader in its industry. If you want to find out what industry the company is involved in, a brief outline of its history and other interesting information, then continue to read on.
Amicus Therapeutics is a biopharmaceutical company (GoogleFinance). Their headquarters is in Cranbury, New Jersey and they are a publicly traded company. Before the company went public, various venture capital firms funded them. Some of the firms that funded Amicus Therapeutics were Canaan Partners, Radius Ventures, and New Enterprise Associates.
On the NASDAQ, the company is traded as FOLD. As for when the company was founded, it was started in 2002 and since then it has grown to become a company that employs many people.
The company was founded in 2002 (http://www.phillypurge.com/2017/08/02/amicus-therapeutics-the-fight-against-the-rare-diseases/). Amicus Therapeutics focuses mainly on rare and orphan diseases. By 2014, Amicus Therapeutics had one of the broadest portfolios of tiny molecules chaperones in the industry. Since the beginning of 2014, the company has no products that are marketed. Migalastat is the company’s lead product.
Amicus Therapeutics has received a number of grants throughout the years. One grant was to support its studies with David Geffen School of Medicine at the University of California in Los Angeles. Another grant was to support their work with with the Icahn School of Medicine’s Alzheimer’s research center.
The CEO of Amicus Therapeutics is John F. Crowley and he has worked in the industry for over 15 years. Other key figures at the company include Bradley Campbell (COO), Chip Baird (CFO) and Daphne Quimi (senior vice president).
For those interested in learning more about what Amicus Therapeutics have to offer, then visit their website. The company’s website also has information about their locations, careers and much more. Now you know more about Amicus Therapeutics, what they do and who leads the company. It’s safe to say that Amicus Therapeutics will remain a leader in the biopharmaceutical industry.